Search

Displaying results 2661 - 2670 of 5419 in total
  1. Drug

    Sulfameter

    go.drugbank.com/drugs/DB06821
    Approved

    Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Gadoteric acid

    go.drugbank.com/drugs/DB09132
    ApprovedInvestigational

    [A263141,A263106] Gadoterate is approved by the FDA under the brand name DOTAREM on 20th March 2013 for intravenous uses with magnetic resonance imaging (MRI) in the brain (intracranial), spine, and

  3. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients.

  4. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    [L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain

  5. Drug

    VIT-100

    go.drugbank.com/drugs/DB05865
    Experimental

    VIT-100 was developed by ItherX Pharmaceuticals of San Diego.

  6. Drug

    Succinobucol

    go.drugbank.com/drugs/DB05399
    Investigational

    AGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary

  7. Drug

    Magnesium citrate

    go.drugbank.com/drugs/DB11110
    ApprovedInvestigational

    [T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg.

  8. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]

  9. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.

  10. Drug

    Hydrocortamate

    go.drugbank.com/drugs/DB00769
    Approved

    Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic